HBV-IN-16

• Description :

  HBV-IN-16 is a potent inhibitor of covalently closed circular DNA (cccDNA) . cccDNA serves as the template for viral RNA transcription and subsequent viral DNA generation. HBV-IN-16 is a quinoline derivative. HBV-IN-16 has the potential for the research of HBV infection (extracted from patent WO2019121357A1, compound 1) [1].

• UNSPSC :

  12352005

• Target :

  DNA/RNA Synthesis; HBV

• Type :

  Reference compound

• Related Pathways :

  Anti-infection; Cell Cycle/DNA Damage

• Applications :

  COVID-19-anti-virus

• Field of Research :

  Infection

• Assay Protocol :

  https://www.medchemexpress.com/hbv-in-16.html

• Solubility :

  10 mM in DMSO

• Smiles :

  ClC1=CC=CC2=C1N=C(C3=CC=C(C=C3)OCCO[C@H]4C[C@H](C4)C(O)=O)C=C2

• Molecular Formula :

  C22H20ClNO4

• Molecular Weight :

  397.85

• References & Citations :

  [1] Song Feng, et al. Novel quinoline compounds for the treatment and prophylaxis of hepatitis b virus disease. Patent WO2019121357A1.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [2355225-38-4]